Your browser doesn't support javascript.
loading
Telomere Maintenance-Associated PML Is a Potential Specific Therapeutic Target of Human Colorectal Cancer.
Gong, Peng; Wang, Hua; Zhang, Jingsong; Fu, Yudong; Zhu, Zhengmao; Wang, Jinmiao; Yin, Yu; Wang, Haiying; Zhou, Zhongcheng; Yang, Jiao; Liu, Linlin; Gou, Mo; Zeng, Ming; Yuan, Jinghua; Wang, Feng; Pan, Xinghua; Xiang, Rong; Weissman, Sherman M; Qi, Feng; Liu, Lin.
Afiliación
  • Gong P; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Wang H; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Zhang J; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • Fu Y; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Zhu Z; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Wang J; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • Yin Y; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Wang H; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Zhou Z; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Yang J; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Liu L; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Gou M; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Zeng M; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China.
  • Yuan J; Department of Genetics, Tianjin Medical University, Tianjin, 300070, China.
  • Wang F; Department of Genetics, Tianjin Medical University, Tianjin, 300070, China.
  • Pan X; Department of Genetics, Yale School of Medicine, New Haven, CT, 06520, USA.
  • Xiang R; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy.
  • Weissman SM; Department of Genetics, Yale School of Medicine, New Haven, CT, 06520, USA.
  • Qi F; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China. Electronic address: qf@medmail.com.cn.
  • Liu L; State Key Laboratory of Medicinal Chemical Biology, 2011 Collaborative Innovation Center for Biotherapy; Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, 300071, China. Electronic address: liulin@nankai.edu.cn.
Transl Oncol ; 12(9): 1164-1176, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31207547
ABSTRACT
Telomere length maintenance is essential for cell proliferation, which is particularly prominent in cancer. We validate that the primary colorectal tumors exhibit heterogeneous telomere lengths but mostly (90%) short telomeres relative to normal tissues. Intriguingly, relatively short telomeres are associated with tumor malignancy as indicated by poorly differentiated state, and these tumors contain more cancer stem-like cells (CSLCs) identified by several commonly used markers CD44, EPHB2 or LGR5. Moreover, promyelocytic leukemia (PML) and ALT-associated PML nuclear bodies (APBs) are frequently found in tumors with short telomeres and high proliferation. In contrast, distant normal tissues rarely or only minimally express PML. Inhibition of PML and APBs by an ATR inhibitor decreases proliferation of CSLCs and organoids, suggesting a potential therapeutic target to progressive colorectal tumors. Together, telomere maintenance underling tumor progression is connected with CSLCs.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Transl Oncol Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Transl Oncol Año: 2019 Tipo del documento: Article País de afiliación: China